Dermata Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	2	2	5	14	-	-
Market Cap Growth	-	-60.70%	-65.84%	-	-	-
Enterprise Value	-5	-5	-1	4	3	-1
PE Ratio	-0.25	-0.25	-0.51	-1.38	-	-
PB Ratio	0.37	0.31	0.82	1.43	-	-
P/FCF Ratio	-0.30	-0.30	-0.56	-2.55	-	-
P/OCF Ratio	-0.30	-0.30	-0.56	-2.55	-	-
EV/EBITDA Ratio	0.70	0.70	0.13	-0.47	-0.99	0.16
EV/EBIT Ratio	0.70	0.70	0.13	-0.47	-0.99	0.16
EV/FCF Ratio	0.86	0.86	0.15	-0.65	-0.75	0.18
Debt / Equity Ratio	-	-	-	-	-1.12	-6.11
Debt / EBITDA Ratio	-	-	-	-	-1.17	-0.29
Debt / FCF Ratio	-	-	-	-	-0.88	-0.33
Quick Ratio	-	-	-	7.12	0.14	1.16
Current Ratio	-	-	-	7.66	0.16	1.20
Interest Coverage	-	-	-	-172.25	-15.41	-17.83
Return on Equity (ROE)	-108.00%	-108.00%	-124.00%	-183.60%	191.10%	-
Return on Assets (ROA)	-93.60%	-93.60%	-106.80%	-149.00%	-242.30%	-
Return on Capital (ROIC)	-126.54%	-126.54%	-160.66%	-77.74%	-862.89%	-416.42%
Earnings Yield	-327.98%	-400.69%	-194.17%	-72.21%	-	-
FCF Yield	-269.67%	-329.46%	-178.48%	-39.29%	-	-
Buyback Yield / Dilution	-323.42%	-323.42%	-156.86%	-125.13%	-	-
Total Shareholder Return	-323.42%	-323.42%	-156.86%	-125.13%	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).